Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on May 17, 2016. The filing details the results of the Company's Annual Meeting of Stockholders held on the same date. A total of 23,670,020 shares were represented, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Four proposals were submitted to stockholders, all of which were approved:
- Proposal 1 (Election of Directors): All six nominees were elected. Dr. Rodney S. Markin received the highest "For" vote count (11,991,312), while Dr. Paul Billings received the lowest (6,807,965). There were no "Against" votes for any director.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2016. The vote was 22,003,089 "For" versus 1,576,887 "Against."
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved with 11,514,404 "For" votes and 2,012,072 "Against" votes.
- Proposal 4 (Equity Plan Amendment): Stockholders approved an amendment to the 2014 Equity Incentive Plan to increase the number of shares reserved for issuance from 5,000,000 to 7,500,000. The vote was 10,455,045 "For" versus 3,131,159 "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the final vote tallies.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the increased share reserve for the 2014 Equity Incentive Plan (now 7,500,000 shares) and its potential dilution impact.
- Review the Definitive Proxy Statement filed on March 31, 2016, for detailed biographies of the elected directors and executive compensation specifics.
- Note the significant number of Broker Non-Votes (9,992,482) on director elections and executive compensation, indicating shares held by brokers that were not voted on these matters.